Etelcalcetide (Parsabiv): Uses, Evidence, and Side Effects

Patients on hemodialysis whose parathyroid glands overproduce hormone often need a targeted treatment option. Etelcalcetide, sold as Parsabiv, is an injectable therapy developed for exactly this problem.

Key takeaways

• Etelcalcetide (Parsabiv) is approved to treat secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis.
• It works by modulating the calcium-sensing receptor on parathyroid cells to reduce hormone secretion.
• It is not recommended for parathyroid carcinoma, primary hyperparathyroidism, or CKD patients who are not on hemodialysis.
• 24 registered clinical trials include work on cardiac effects and a head-to-head comparison with cinacalcet.
• Reported adverse events most often involve low calcium levels, dosing or storage errors, and dialysis shunt problems.

What Etelcalcetide Is

Etelcalcetide belongs to a class of drugs called calcimimetics, which act on the calcium-sensing receptor (CaSR). It binds to this receptor and boosts its response to calcium already present in the blood. Because activating the CaSR on parathyroid chief cells lowers parathyroid hormone (PTH) secretion, the drug helps bring PTH levels down in dialysis patients whose glands are overactive.

What Etelcalcetide Is Approved For

Parsabiv, the approved brand of etelcalcetide, treats secondary hyperparathyroidism in adults with chronic kidney disease who are on hemodialysis. The label specifically notes limitations of use: the drug has not been studied in patients with parathyroid carcinoma, primary hyperparathyroidism, or CKD without hemodialysis, and is not recommended for those groups. No boxed warning is present on the label.

What The Evidence Shows

Etelcalcetide has been studied across 24 registered clinical trials. A completed Phase 4 trial examined its effect on cardiac hypertrophy in hemodialysis patients, looking beyond parathyroid hormone control to heart-related outcomes. A completed Phase 3 trial compared etelcalcetide directly against cinacalcet, another calcimimetic, to evaluate relative performance.

Reported Side Effects

Adverse event reports for etelcalcetide most frequently involve disruptions to calcium and hormone balance, including hypocalcaemia (149 reports), decreased blood calcium (124), and increased blood parathyroid hormone (145). Dialysis access complications also appear often, with shunt stenosis (204 reports) and shunt occlusion (127). Other frequently reported issues include underdosing (247), product storage errors (149), and nausea (192). These figures reflect submitted reports, not confirmed incidence rates or established causation.